Oculis Holding (OCS)

• Market cap: $678M
• 1 day: -0.71%
• 5 days: 1.91%
• 1 month: -60.03%
• 3 months: -57.34%
• 6 months: -42.4%
• Year to date: -43.9%
• 1 year: -42.4%
• 5 years: 3.03%
• 10 years: 3.03%
• Sector: Healthcare
• Industry: Biotechnology

About: Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.

Employees: 60